BridgeBio Pharma Says Acoramidis Reduces CVM Or CVH Risk By 49% Through Month 30

RefinitivLess than 1 min read

BridgeBio Pharma Inc BBIO:

ACORAMIDIS BEGINS TO REDUCE CUMULATIVE CARDIOVASCULAR OUTCOMES WITHIN THE FIRST MONTH OF TREATMENT IN PATIENTS WITH ATTR-CM
BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES CVM OR CVH RISK BY 49% THROUGH MONTH 30

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Login or create a forever free account to read this news